Shire planning chief opts for early exit
MORNINGTON Peninsula Shire’s planning and building director David Bergin resigned last week.
Mr Bergin, one of the council’s highest paid “key management personnel” was with the shire for five years after stints at Swan Hill, Boroondara and Mitchell Shire and local government in the UK.
Shire staff learned of his “immediate resignation for a variety of personal reasons” in a farewell email to staff on Thursday 18 February.
Mr Bergin said CEO Johan Baker had “kindly allowed me to end my contract early”.
He was leaving the shire “having followed and displayed all our values, including courage, openness, respect, excellence and, at all times, I have maintained my integrity”.
Nasdaq Moves Sharply Lower In Morning Trading, Dow Posting Modest Loss
WASHINGTON (dpa-AFX) - Stocks have moved mostly lower in morning trading on Monday after ending the previous session nearly unchanged. The major averages have all moved to the downside, with the tech-heavy Nasdaq showing a particularly steep drop.
The Dow has climbed well off its worst levels of the day but remained down 99.44 points or 0.3 percent at 31,394.88. The Nasdaq is down 199.43 points or 1.4 percent at 13,675.03 and the S&P 500 is down 25.34 points or 0.7 percent at 3,881.37.
The weakness on Wall Street partly reflects concerns about the outlook for inflation following the recent advance by bond yields.
Deadly diet for birds - Bayside News baysidenews.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baysidenews.com.au Daily Mail and Mail on Sunday newspapers.
New asthma treatment results ‘amazing’
DOCTORS at Frankston Hospital are leading the line for a new treatment for asthmatics.
A program at the hospital has been treating asthma patients with injections. Peninsula Health’s director of thoracic medicine Associate Professor David Langton has been in charge of the program.
“We have been involved with asthma research for over 10 years and are pleased to be at the forefront of new treatments for our patients” Mr Langton said.
“The results of the treatments to date are amazing. About 95 per cent of patients are improved, often greatly so, with marked reductions in asthma symptoms, reductions in exacerbations, reductions in the need for reliever medication, and improvements in lung function.